CTOs on the Move

Symic Biomedical

www.symic.bio

 
Symic is developing a new category of therapeutics that offer an exciting and biologically innovative approach to treating disease. While it is clear that cells play an important role in tissue inflammation and regeneration, it is also known that the extracellular matrix (ECM) plays an equally critical role in maintaining healthy tissue. The ECM is the non-cellular component of the body’s tissues, and proteoglycans are important structural and functional macromolecules native to the ECM that are known to protect against tissue degradation and promote healing during illness or injury. Recognizing the importance of proteoglycans in many acute and chronic disease states, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.symic.bio
  • 953 Indiana Street
    San Francisco, CA USA 94107
  • Phone: 415.805.9005

Executives

Name Title Contact Details

Funding

Symic Biomedical raised $25M on 12/01/2015
Symic Biomedical raised $11M on 04/25/2019

Similar Companies

The Degge Group

The Degge Group is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sapphire Biotech

Sapphire Biotech, Inc.`s diagnostic tool is being used to study the company`s enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells.

Gilson

Gilson is a Middleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Therapure

Therapure is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xcell Biosciences

Xcell Bio is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell`s mission is to democratize maintenance, expansion and control of any primary cell type through its bench-top primary cell control systems, reagent kits, software, and standardized protocols. The technology delivers simple control of primary cell types from blood or solid tissue, including a range of immune cells, stem cells, and tumor cells. This patient-centric technology offers a unique and proprietary capability to improve immunotherapy efficacy, safety, and persistence through more predictive and iterative therapy development and rapid, highly-controlled clinical cell manufacturing.